Additional File 1
Patients were grouped based on quartiles of PTH decrease from first cinacalcet prescription.
Patients whose PTH levels increased or remained unchanged were assigned to "no PTH reduction" group.
Results are reported as percent of patients or mean ± SD. P values: We used analysis of variance Patients were grouped based on quartiles of PTH decrease from first cinacalcet prescription.
Results are reported as percent of patients or mean ± SD. P values: We used analysis of variance (ANOVA) and chi-square tests to evaluate differences in continuous and categorical characteristics, respectively, across all PTH change groups.
ASHD, atherosclerotic heart disease; BMI, body mass index determined using height and weight;
CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVA/TIA, cerebral vascular accident/transient ischemic attack; ESRD, end-stage renal disease; GI, gastrointestinal; PTH, parathyroid hormone; PVD, peripheral vascular disease; SD, standard deviation.
